0001564590-20-057719.txt : 20201218 0001564590-20-057719.hdr.sgml : 20201218 20201218171728 ACCESSION NUMBER: 0001564590-20-057719 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20201214 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201218 DATE AS OF CHANGE: 20201218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 201401523 BUSINESS ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE, SUITE 240 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-207-4264 MAIL ADDRESS: STREET 1: 4747 EXECUTIVE DRIVE, SUITE 240 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 ljpc-8k_20201214.htm 8-K WATERTOWN LEASE TERMINATION ljpc-8k_20201214.htm
false 0000920465 0000920465 2020-12-14 2020-12-14

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report: December 14, 2020

(Date of earliest event reported)

LA JOLLA PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

Commission File Number: 1-36282

 

California

 

33-0361285

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

4747 Executive Drive, Suite 240, San Diego, California 92121

(Address of principal executive offices, including zip code)

(858) 207-4264

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

 

LJPC

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.02Termination of a Material Definitive Agreement.

On December 14, 2020, Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla Pharmaceutical Company (“La Jolla”), entered into a Termination of Lease and Voluntary Surrender of Premises Agreement (the “Lease Termination Agreement”) with ARE-480 Arsenal Street, LLC (the “Landlord”) for its office and laboratory space at 480 Arsenal Way, Watertown, Massachusetts (the “Watertown Lease”). The Lease Termination Agreement is effective December 31, 2020. In connection with the Lease Termination Agreement, La Jolla will pay the Landlord approximately $0.5 million and will otherwise have no further obligations under the Watertown Lease, including with respect to the estimated remaining $3.3 million of future lease payments.

 

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

 

Exhibit

No.

  

Description

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

LA JOLLA PHARMACEUTICAL COMPANY

 

 

 

 

Date: December 18, 2020

By:

 

/s/ Michael Hearne

 

 

 

Michael Hearne

 

 

 

Chief Financial Officer

 

 EX-101.SCH 2 ljpc-20201214.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 ljpc-20201214_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 ljpc-20201214_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 ljpc-8k_20201214_htm.xml IDEA: XBRL DOCUMENT 0000920465 2020-12-14 2020-12-14 false 0000920465 8-K 2020-12-14 LA JOLLA PHARMACEUTICAL COMPANY 1-36282 CA 33-0361285 4747 Executive Drive Suite 240 San Diego CA 92121 858 207-4264 false false false false Common Stock, par value $0.0001 per share LJPC NASDAQ false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Dec. 14, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000920465
Document Type 8-K
Document Period End Date Dec. 14, 2020
Entity Registrant Name LA JOLLA PHARMACEUTICAL COMPANY
Entity File Number 1-36282
Entity Incorporation, State or Country Code CA
Entity Tax Identification Number 33-0361285
Entity Address, Address Line One 4747 Executive Drive
Entity Address, Address Line Two Suite 240
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 207-4264
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol LJPC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ljpc-8k_20201214.htm ljpc-20201214.xsd ljpc-20201214_lab.xml ljpc-20201214_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ljpc-8k_20201214.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "ljpc-8k_20201214.htm" ] }, "labelLink": { "local": [ "ljpc-20201214_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ljpc-20201214_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ljpc-20201214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ljpc", "nsuri": "http://www.lajollapharmaceutical.com/20201214", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "ljpc-8k_20201214.htm", "contextRef": "C_0000920465_20201214_20201214", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "ljpc-8k_20201214.htm", "contextRef": "C_0000920465_20201214_20201214", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lajollapharmaceutical.com/20201214/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001564590-20-057719-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-057719-xbrl.zip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end